These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29769963)

  • 1. Summary of the National Advisory Committee on Immunization's Update on quadrivalent meningococcal vaccines available in Canada.
    Henry B;
    Can Commun Dis Rep; 2015 Apr; 41(Suppl 3):17-18. PubMed ID: 29769963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of the National Advisory Committee on Immunization's updated recommendations on human papillomavirus (HPV) vaccines: Nine-valent human papillomavirus (HPV) of minimum intervals between doses in the HPV immunization schedule.
    Tunis MC; Deeks SL;
    Can Commun Dis Rep; 2016 Jul; 42(7):149-151. PubMed ID: 29770021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
    Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
    Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
    Croxtall JD; Dhillon S
    Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease.
    Harrison R; Stirling R; Baclic O; Vaudry W
    Can Commun Dis Rep; 2020 Feb; 46(2-3):36-39. PubMed ID: 32167082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
    Áñez G; Hedrick J; Simon MW; Christensen S; Jeanfreau R; Yau E; Pan J; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2020 Jun; 16(6):1292-1298. PubMed ID: 32209015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
    Marshall GS; Pelton SI; Robertson CA; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion.
    Ricci S; Azzari C; Amodio E; Castiglia P
    Expert Rev Vaccines; 2023; 22(1):447-456. PubMed ID: 37144288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.
    Hedari CP; Khinkarly RW; Dbaibo GS
    Infect Drug Resist; 2014; 7():85-99. PubMed ID: 24729718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
    Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT.
    Martinón-Torres F; Bertrand-Gerentes I; Oster P
    Expert Rev Vaccines; 2021 Sep; 20(9):1123-1146. PubMed ID: 34365870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)
    van der Vliet D; Vesikari T; Sandner B; Martinón-Torres F; Muzsay G; Forsten A; Adelt T; Diaz Gonzalez C; Simko R; B'Chir S; Neveu D; Jordanov E; Dhingra MS
    Epidemiol Infect; 2021 Feb; 149():e50. PubMed ID: 33541457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vesikari T; Forsten A; Laudat F; Li P; Van Der Wielen M; Hezareh M; Perez JL; Webber C
    Vaccine; 2020 May; 38(22):3902-3908. PubMed ID: 32284274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
    Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
    Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Summary of the National Advisory Committee on Immunization's Statement on the re-immunization with polysaccharide 23-valent pneumococcal vaccine.
    Quach C;
    Can Commun Dis Rep; 2015 Apr; 41(Suppl 3):14-16. PubMed ID: 29769962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.
    Ghanem S; Hassan S; Saad R; Dbaibo GS
    Expert Opin Biol Ther; 2013 Aug; 13(8):1197-205. PubMed ID: 23815506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.